jRCT2021250041招募中不适用
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged >=1 to <36 Years (I4V-MC-JAJJ)
未提供0 个研究点目标入组 150 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 1age old over 至 35age old under（—）
- 性别
- All
入选标准
- •Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening
- •Have Stage 1b or Stage 2 type 1 diabetes
- •Have a body weight of >=8 kilograms (kg) (18 pounds) at screening
排除标准
- •Have any other type of diabetes
- •Have uncontrolled high blood pressure
- •Have had a heart attack, heart disease, stroke, or heart failure
- •Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- •Have a current or recent clinically serious infection
研究者
相似试验
招募中
不适用
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (J3R-MC-YDAG)Obesity OverweightObesity
OverweightjRCT20312508011,980
招募中
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features,in Bipolar-I Disorder TakingLithium, Valproate, or Lamotrigine (CN0120046)Bipolar-I DisorderjRCT204125017027
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATX304Obesity/overweight (healthy subjects)2024-514744-91-00Betagenon AB, Betagenon AB40
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy ParticipantsSchizophrenia2025-521914-25-00Clexio Biosciences Ltd.110
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of GTX-11 in Healthy SubjectsPulmonary fibrosis2023-504426-19-00Gat Therapeutics S.L.52